CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma.
Biomarker
Gene expression
Immune
Prediction
Prognosis
Journal
Functional & integrative genomics
ISSN: 1438-7948
Titre abrégé: Funct Integr Genomics
Pays: Germany
ID NLM: 100939343
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
received:
26
08
2023
accepted:
13
10
2023
revised:
12
10
2023
medline:
13
11
2023
pubmed:
11
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
The roles of cyclin-dependent kinase 6 (CDK6) in various cancers, including small cell lung carcinoma (SCLC), remain unclear. Here, 111,54 multi-center samples were investigated to determine the expression, clinical significance, and underlying mechanisms of CDK6 in 34 cancers. The area under the curve (AUC), Cox regression analysis, and the Kaplan-Meier curves were used to explore the clinical value of CDK6 in cancers. Gene set enrichment analysis and correlation analysis were performed to detect potential CDK6 mechanisms. CDK6 expression was essential in 24 cancer cell types. Abnormal CDK6 expression was observed in 14 cancer types (e.g., downregulated in breast invasive carcinoma; p < 0.05). CDK6 allowed six cancers to be distinguished from their controls (AUC > 0.750). CDK6 expression was a prognosis marker for 13 cancers (e.g., adrenocortical carcinoma; p < 0.05). CDK6 was correlated with several immune-related signaling pathways and the infiltration levels of certain immune cells (e.g., CD8
Identifiants
pubmed: 37950078
doi: 10.1007/s10142-023-01253-3
pii: 10.1007/s10142-023-01253-3
doi:
Substances chimiques
Cyclin-Dependent Kinase 6
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
332Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Anuraga G et al (2021) Potential prognostic biomarkers of NIMA (never in mitosis, gene A)-related kinase (NEK) family members in breast cancer. J Pers Med 11(11). https://doi.org/10.3390/jpm11111089
Barretina J et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603–607. https://doi.org/10.1038/nature11003
doi: 10.1038/nature11003
Barta JA et al (2019) Global Epidemiology of Lung Cancer. Ann Glob Health 85(1). https://doi.org/10.5334/aogh.2419
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
doi: 10.2307/2533446
Carvalho BS, Irizarry RA (2010) A framework for oligonucleotide microarray preprocessing. Bioinformatics 26(19):2363–2367. https://doi.org/10.1093/bioinformatics/btq431
doi: 10.1093/bioinformatics/btq431
Fassl A et al (2022) CDK4 and CDK6 kinases: from basic science to cancer therapy. Science 375(6577):eabc1495. https://doi.org/10.1126/science.abc1495
doi: 10.1126/science.abc1495
George J et al (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524(7563):47–53. https://doi.org/10.1038/nature14664
doi: 10.1038/nature14664
Gong W et al (2020) Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer. Transl Cancer Res 9(1):95–103. https://doi.org/10.21037/tcr.2019.11.21
doi: 10.21037/tcr.2019.11.21
Gu JF et al (2020) Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells. Anat Rec (Hoboken) 303(11):2811–2820. https://doi.org/10.1002/ar.24362
doi: 10.1002/ar.24362
Guillerey C (2020) NK cells in the tumor microenvironment. Adv Exp Med Biol 1273:69–90. https://doi.org/10.1007/978-3-030-49270-0_4
doi: 10.1007/978-3-030-49270-0_4
Han R et al (2021) Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma. Cancer Med 10(15):5088–5100. https://doi.org/10.1002/cam4.4065
doi: 10.1002/cam4.4065
Jardim DL et al (2021) Cyclin pathway genomic alterations across 190,247 solid tumors: leveraging large-scale data to inform therapeutic directions. Oncologist 26(1):e78–e89. https://doi.org/10.1634/theoncologist.2020-0509
doi: 10.1634/theoncologist.2020-0509
Kanehisa M (2019) Toward understanding the origin and evolution of cellular organisms. Protein Sci 28(11):1947–1951. https://doi.org/10.1002/pro.3715
doi: 10.1002/pro.3715
Kanehisa M et al (2021) KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 49(D1):D545–D551. https://doi.org/10.1093/nar/gkaa970
doi: 10.1093/nar/gkaa970
Kao TJ et al (2021) Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer. Aging (Albany NY) 13(14):17970. https://doi.org/10.18632/aging.203345
doi: 10.18632/aging.203345
Ko J et al (2021) Mechanisms of small cell lung cancer metastasis. EMBO Mol Med 13(1):e13122. https://doi.org/10.15252/emmm.202013122
doi: 10.15252/emmm.202013122
Leek JT, Storey JD (2007) Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 3(9):1724–1735. https://doi.org/10.1371/journal.pgen.0030161
doi: 10.1371/journal.pgen.0030161
Li H et al (2017) Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients. Int J Clin Exp Pathol 10(9):9614–9620
Li X et al (2020) Effects of CDK6 regulated by miR-298 on proliferation and apoptosis of thyroid cancer cells. Oncol Lett 19(4):2909–2915. https://doi.org/10.3892/ol.2020.11398
doi: 10.3892/ol.2020.11398
Li M et al (2021) Exosomal miR-92b-3p promotes chemoresistance of small cell lung cancer through the PTEN/AKT pathway. Front Cell Dev Biol 9:661602. https://doi.org/10.3389/fcell.2021.661602
doi: 10.3389/fcell.2021.661602
Li T et al (2020) TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48(W1):W509–W514. https://doi.org/10.1093/nar/gkaa407
doi: 10.1093/nar/gkaa407
Li Z et al (2019) Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. J Exp Clin Cancer Res 38(1):380. https://doi.org/10.1186/s13046-019-1371-0
doi: 10.1186/s13046-019-1371-0
Modhukur V et al (2018) MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics 10(3):277–288. https://doi.org/10.2217/epi-2017-0118
doi: 10.2217/epi-2017-0118
Nardone V et al (2021) CDK4, CDK6/cyclin-D1 complex inhibition and radiotherapy for cancer control: a role for autophagy. Int J Mol Sci 22(16). https://doi.org/10.3390/ijms22168391
Nebenfuehr S et al (2020) The role of CDK6 in cancer. Int J Cancer 147(11):2988–2995. https://doi.org/10.1002/ijc.33054
doi: 10.1002/ijc.33054
Niu JT et al (2019) Study on the mechanism of miR-497-induced laryngeal squamous cell carcinoma growth inhibition by targeting CDK6. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 54(2):126–132. https://doi.org/10.3760/cma.j.issn.1673-0860.2019.02.006
doi: 10.3760/cma.j.issn.1673-0860.2019.02.006
Niu X et al (2022) Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2022.03.009
Pan H et al (2019) miR-4429 inhibits tumor progression and epithelial-mesenchymal transition via targeting CDK6 in clear cell renal cell carcinoma. Cancer Biother Radiopharm 34(5):334–341. https://doi.org/10.1089/cbr.2018.2697
doi: 10.1089/cbr.2018.2697
Poomsawat S et al (2016) Expression of cdk6 in head and neck squamous cell carcinoma. Clin Oral Investig 20(1):57–63. https://doi.org/10.1007/s00784-015-1482-8
doi: 10.1007/s00784-015-1482-8
Ritchie ME et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47. https://doi.org/10.1093/nar/gkv007
doi: 10.1093/nar/gkv007
Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708
doi: 10.3322/caac.21708
Subramanian A et al (2017) A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171(6):1437–1452 e17. https://doi.org/10.1016/j.cell.2017.10.049
doi: 10.1016/j.cell.2017.10.049
Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
Tadesse S et al (2015) Targeting CDK6 in cancer: state of the art and new insights. Cell Cycle 14(20):3220–3230. https://doi.org/10.1080/15384101.2015.1084445
doi: 10.1080/15384101.2015.1084445
Tsoukalas N et al (2018) Advanced small cell lung cancer (SCLC): new challenges and new expectations. Ann Transl Med 6(8):145. https://doi.org/10.21037/atm.2018.03.31
doi: 10.21037/atm.2018.03.31
VanArsdale T et al (2015) Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res 21(13):2905–2910. https://doi.org/10.1158/1078-0432.CCR-14-0816
doi: 10.1158/1078-0432.CCR-14-0816
Wang CY et al (2020) Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. Am J Cancer Res 10(1):95–113
Wang S et al (2019a) Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc 94(8):1599–1622. https://doi.org/10.1016/j.mayocp.2019.01.034
doi: 10.1016/j.mayocp.2019.01.034
Wang YL et al (2019b) Lnc-UCID promotes G1/S transition and hepatoma growth by preventing DHX9-mediated CDK6 down-regulation. Hepatology 70(1):259–275. https://doi.org/10.1002/hep.30613
doi: 10.1002/hep.30613
Xie Z et al (2022) Lessons learned from past cyclin-dependent kinase drug discovery efforts. J Med Chem 65(9):6356–6389. https://doi.org/10.1021/acs.jmedchem.1c02190
doi: 10.1021/acs.jmedchem.1c02190
Xing C et al (2021) Integrate analysis of the promote function of cell division cycle-associated protein family to pancreatic adenocarcinoma. Int J Med Sci 18(3):672–684. https://doi.org/10.7150/ijms.53243
doi: 10.7150/ijms.53243
Xue Y et al (2019) SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun 10(1):557. https://doi.org/10.1038/s41467-019-08380-1
doi: 10.1038/s41467-019-08380-1
Yu G et al (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284–287. https://doi.org/10.1089/omi.2011.0118
doi: 10.1089/omi.2011.0118
Yu M et al (2020) A comparison of mRNA and circRNA expression between squamous cell carcinoma and adenocarcinoma of the lungs. Genet Mol Biol 43(4):e20200054. https://doi.org/10.1590/1678-4685-GMB-2020-0054
doi: 10.1590/1678-4685-GMB-2020-0054
Zhang J et al (2016) miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6. Eur Rev Med Pharmacol Sci 20(21):4494–4499
Zhong D et al (2020) Upregulation of miR-124-3p by liver X receptor inhibits the growth of hepatocellular carcinoma cells Via suppressing cyclin D1 and CDK6. Technol Cancer Res Treat 19:1533033820967473. https://doi.org/10.1177/1533033820967473
doi: 10.1177/1533033820967473